Expression of miRNAs expressed in normal B cells is conserved in B-cell malignancies. (A) A predictor constructed of miRNAs differentially expressed in the normal naive B cells and GC B cells (miRNAs depicted in Figure 1D) was used to predict the normal counterpart B cell of both IgV mutated and unmutated chronic lymphocytic leukemia, GC B cell–derived DLBCL, and Burkitt lymphoma. The accuracy was greater than 95% in all cases. (B) Expression of miRNAs expressed in B cells that also were present and detectably measured on the microarrays (103/113) was examined in the B-cell malignancies (n = 70) and normal lymph nodes (n = 5) with use of the Student t test. miRNAs that were differentially expressed (P < .05) at greater levels in malignant cells, normal cells, as well as the miRNAs that were not differentially expressed are shown. (C) Cloning frequency of miRNAs was compared between unselected mature B cells (n = 3) compared with several B-cell malignancies (n = 42) from a previously published study²⁶  (“sequencing data”) with use of the Student t test. miRNAs that were differentially expressed (P < .05) at greater levels in malignant and normal cells, as well as the miRNAs that were not differentially expressed, are shown. (D) Differentially expressed miRNAs that distinguish Burkitt lymphoma, activated B cell–like (ABC) diffuse large B-cell lymphoma (DLBCL), GC-like DLBCL (GCB DLBCL), and chronic lymphocytic leukemia. Predictor miRNAs from each pairwise comparison that distinguish each entity are shown in the boxes.